Keyphrases
Randomized Placebo-controlled Trial
100%
Controlled Crosses
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
100%
Coronary Microvascular Function
100%
Empagliflozin
100%
Coronary Flow Reserve
42%
Placebo
28%
Cardiovascular Biomarkers
28%
Cardiac Function
28%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
28%
Cardiovascular Mortality
14%
Blood Samples
14%
University Hospital
14%
Outpatient Clinic
14%
Placebo-controlled
14%
Hemoglobin A1c (HbA1c)
14%
Washout Period
14%
Cardiovascular Outcome Trials
14%
Weight Loss
14%
Weight Reduction
14%
Heart Failure Hospitalization
14%
Cardiovascular Hospitalizations
14%
Cardiovascular Effects
14%
Doppler Echocardiography
14%
Creatinine Level
14%
Cardiac Systolic Function
14%
Echocardiographic Parameters
14%
Endocrinology
14%
Serious Adverse Reaction
14%
Treatment Sequence
14%
HbA1c Levels
14%
Simple Randomization
14%
Biomarkers Treatment
14%
Weight-loss Treatment
14%
Cardiac Filling Pressures
14%
Medicine and Dentistry
Placebo
100%
Maturity Onset Diabetes of the Young
100%
Patient with Type 2 Diabetes
100%
Empagliflozin
100%
Cardiovascular System
57%
Biological Marker
42%
Coronary Flow Reserve
42%
Hemoglobin A1c
28%
Heart Function
28%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Outpatient
14%
Adverse Event
14%
Heart Failure
14%
Systolic Function
14%
Creatinine
14%
Cardiovascular Effect
14%
Doppler Echocardiography
14%
Endocrinology
14%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Non Insulin Dependent Diabetes Mellitus
100%
Empagliflozin
100%
Biological Marker
42%
Hemoglobin A1c
28%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Adverse Event
14%
Creatinine
14%
Heart Failure
14%